



Keytruda in Qatar

The MOPH named-patient import pathway — indicative 2026

ONCOLOGY · ANTI-PD-1 MULTI-TUMOUR IMMUNOTHERAPY

The clinical situation

Keytruda (pembrolizumab) is an FDA-approved anti-PD-1 monoclonal antibody given as an IV infusion every three or six weeks across more than a dozen solid-tumour indications — NSCLC, melanoma, head-and-neck, urothelial, triple-negative breast, renal cell, certain GI cancers, and a tissue-agnostic MSI-high / mismatch-repair-deficient indication. Developed by Merck. Eligibility depends on tumour type, line of therapy, and biomarker status (PD-L1, MSI/MMR, TMB) per FDA labeling. Baseline autoimmune screening and on-treatment immune-related adverse-event (irAE) surveillance are standard.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating oncologist confirms tumour type, biomarker status where relevant, line history, and documents a written clinical rationale.
- 2 Infusion facility confirmed.** A Qatar oncology day-unit with cold-chain storage is identified; most tertiary centres already administer anti-PD-1 therapy routinely.
- 3 MOPH named-patient application.** Hospital pharmacy files with MOPH, including clinical rationale, QCHP licensure verification, and the irAE surveillance plan.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; cold-chain shipment with continuous temperature monitoring.
- 5 Arrival & first infusion.** Hospital pharmacy releases doses to the oncology day-unit for administration on your cycle schedule; subsequent cycles ship on a rolling basis.

Indicative economics

Reference US cash-pay range: USD 10,000–12,000 per 200 mg dose; cycle cost driven by 3-weekly (200 mg) vs 6-weekly (400 mg) dosing interval. Cold-chain logistics, MOPH documentation handling, and concierge coordination are incremental. Full transparent quote at intake.

Indicative first-dose timing

10–21 days from a complete MOPH application to first infusion, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and MOPH review, including irAE surveillance template. **Logistics.** Cold-chain, temperature-monitored shipment coordination. **Concierge case lead.** Named point of contact for family and physician through intake and cycle-to-cycle refills.

We are a coordinator — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating oncologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Keytruda × Qatar first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/keytruda-qatar.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team